Topic 6
Development of New Broad Spectrum Anticancer Drugs
The goal of the proposed project is to develop new broad spectrum anticancer drugs using an innovative and non-traditional approach where we create highly potent small molecules with a simple 3-component “A-B-C” structure (500-700 daltons) and nanmolar activity.
Publications
2015-2019
- Avdieiev, S.S., L. Gera, R. Hodges and V.V. Dmytrenke. Glioma-associated protein CHI3L2 suppresses cells viability and induces G1/S transition arrest. Biopolymers and Cell, 31: 316-320 (2015).
- Avidieve, S., L. Gera, D. Havryl, R.S. Hodges, R. Lesyk, V. Ribrag, Y. Vassetzky, V. Kavsan. Development of effective drug combinations for glioblastoma and mantle cell lymphoma treatment. In Biopolymers Cell, Special issue, 31: 20-22 (2015).
2010-2014
- Avdieiev, S., Gera, L., Havrylyuk, D., Hodges, R.S., Lesyk, R., Ribrag, V., Vassetzky, Y., Kavsan, V. (2014). Bradykinin antagonists and thiazolidinone derivatives as new potential anti-cancer compounds. Biorg.Med. Chem. 22:3815-3823.
- Avdieiev, S.S., Gera, L., Hodges, R., Vassetzky, Y.S., Kavsan, V.M. (2014). Growth suppression activity of bradykinin antagonists in glioma cells. Biopolym. Cell 30(1), 77-79.
- Baumgartner, H.K., N. Beeman, R.S. Hodges and M.C. Neville. A D-peptide analog of the second extracellular loop of claudin-3 and -4 leads to mis-localized claudin and cellular apoptosis in mammary epithelial cells. Chem. Biol. & Drug Design 77: 124-136 (2011). (Journal Cover Figure) PMC3080100 PMID21266016
Proceedings Publications
2015-2019
- Gera, L., J. Tentler, S.G. Eckhardt, Z. Jiang, A. D’Alessandro and R.S. Hodges. Development of novel broad spectrum anticancer small molecule peptidomimetics with nanomolar activity. In Enabling Peptide Research from Basic Research to Drug Discovery, Proceedings of the 24th American Peptide Symposium, Orlando, FL (V. Srivastava, A. Yudin and M. Lebl, editors) pp. 241-244 (2015) Published by the American Peptide Society and Propt Scientific Publishing, 2015.
2010-2014
N/A